Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), and other diseases driven by dysregulated aldosterone. The company announced today that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, which takes place in Las Vegas from May 14-16, 2024.
The fireside chat featuring Mineralys Therapeutics will be held on Wednesday, May 15, 2024, at 5:00pm PDT. A live webcast of the event will be available on the company’s website at www.mineralystx.com and can be accessed under “News and Events” in the Investor Relations section. Additionally, a replay of the fireside chat will be accessible on the website for approximately 90 days after the event.
Mineralys Therapeutics is dedicated to developing medicines for various conditions that are caused by dysregulated aldosterone. Their lead product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed for cardiorenal conditions affected by dysregulated aldosterone. The company is based in Radnor, Pennsylvania and was founded by Catalys Pacific. For more information about Mineralys Therapeutics please visit their website at https://mineralystx.com or follow them on LinkedIn and Twitter.
For investor relations inquiries please contact investorrelations@mineralystx.com and for media relations reach out to Tom Weible at Elixir Health Public Relations by phone at (1) 515-707-9678 or email at tweible@elixirhealthpr.com